Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4703)
All Articles published online
|
Publishing Process of This Article
|
Mar 27, 2022 (publication date) through Apr 29, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Manzhalii E, Moyseyenko V, Kondratiuk V, Molochek N, Falalyeyeva T, Kobyliak N. Effect of a specific Escherichia coli Nissle 1917 strain on minimal/mild hepatic encephalopathy treatment. World J Hepatol 2022; 14(3): 634-646 [PMID: 35582294 DOI: 10.4254/wjh.v14.i3.634] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v14/i3/634.htm |
| Number | Citing Articles |
| 1 |
Frances Widjaja, Ivonne M. C. M. Rietjens. From-Toilet-to-Freezer: A Review on Requirements for an Automatic Protocol to Collect and Store Human Fecal Samples for Research Purposes. Biomedicines 2023; 11(10): 2658 doi: 10.3390/biomedicines11102658
|
| 2 |
Rachel Redfield, Nyan Latt, Santiago J. Munoz. Minimal Hepatic Encephalopathy. Clinics in Liver Disease 2024; 28(2): 237 doi: 10.1016/j.cld.2024.01.004
|
| 3 |
Ming Luo, Rui-Juan Xin, Fang-Rui Hu, Li Yao, Sheng-Juan Hu, Fei-Hu Bai. Role of gut microbiota in the pathogenesis and therapeutics of minimal hepatic encephalopathy <i>via </i>the gut-liver-brain axis. World Journal of Gastroenterology 2023; 29(1): 144-156 doi: 10.3748/wjg.v29.i1.144
|
| 4 |
Sergii Tkach, Andrii Dorofeyev, Iurii Kuzenko, Nadiya Boyko, Tetyana Falalyeyeva, Nazarii Kobyliak. Microbiome in 3P Medicine Strategies. Advances in Predictive, Preventive and Personalised Medicine 2023; 16: 275 doi: 10.1007/978-3-031-19564-8_10
|
| 5 |
Garima Mishra, Pradeep Singh, Mulugeta Molla, Yohannes Shumet Yimer, Subas Chandra Dinda, Phool Chandra, Bhuvnesh Kumar Singh, Samuel Berihun Dagnew, Abraham Nigussie Assefa, Amien Ewunetie. Harnessing the potential of probiotics in the treatment of alcoholic liver disorders. Frontiers in Pharmacology 2023; 14 doi: 10.3389/fphar.2023.1212742
|
| 6 |
Harry D Zacharias, Fady Kamel, Jaclyn Tan, Nina Kimer, Lise Lotte Gluud, Marsha Y Morgan. Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database of Systematic Reviews 2023; 2023(7) doi: 10.1002/14651858.CD011585.pub2
|
| 7 |
Sergii Tkach, Andrii Dorofeyev, Iurii Kuzenko, Oksana Sulaieva, Tetyana Falalyeyeva, Nazarii Kobyliak. Fecal microbiota transplantation in patients with post-infectious irritable bowel syndrome: A randomized, clinical trial. Frontiers in Medicine 2022; 9 doi: 10.3389/fmed.2022.994911
|
| 8 |
Cynthia L. Hsu, Bernd Schnabl. The gut–liver axis and gut microbiota in health and liver disease. Nature Reviews Microbiology 2023; 21(11): 719 doi: 10.1038/s41579-023-00904-3
|
| 9 |
Jie Gao, Rui Nie, Hong Chang, Wei Yang, Qian Ren. A meta-analysis of microbiome therapies for hepatic encephalopathy. European Journal of Gastroenterology & Hepatology 2023; 35(9): 927 doi: 10.1097/MEG.0000000000002596
|
| 10 |
Fan Xue, Zheng He, De-Zheng Zhuang, Feng Lin. The influence of gut microbiota on circulating inflammatory cytokines and host: A Mendelian randomization study with meta-analysis. Life Sciences 2023; 332: 122105 doi: 10.1016/j.lfs.2023.122105
|
| 11 |
Ming Yang, Katina Massad, Eric T. Kimchi, Kevin F. Staveley-O’Carroll, Guangfu Li. Gut microbiota and metabolite interface-mediated hepatic inflammation. Immunometabolism 2024; 6(1): e00037 doi: 10.1097/IN9.0000000000000037
|
| 12 |
Xing Yang, Langhuan Lei, Wei Shi, Xiaozhen Li, Xiaozhi Huang, Liuyan Lan, Jiali Lin, Qiuyu Liang, Wei Li, Jianrong Yang. Probiotics are beneficial for liver cirrhosis: a systematic review and meta-analysis of randomized control trials. Frontiers in Medicine 2024; 11 doi: 10.3389/fmed.2024.1379333
|
| 13 |
Roman Maslennikov, Aliya Alieva, Elena Poluektova, Yury Zharikov, Andrey Suslov, Yana Letyagina, Ekaterina Vasileva, Anna Levshina, Evgenii Kozlov, Vladimir Ivashkin. Sarcopenia in cirrhosis: Prospects for therapy targeted to gut microbiota. World Journal of Gastroenterology 2023; 29(27): 4236-4251 doi: 10.3748/wjg.v29.i27.4236
Abstract(374) |
Core Tip(330) |
Full Article(HTML)(2278)
|
Full Article with Cover (PDF)-2077K(55)
|
Full Article (Word)-351K(50)
|
Audio-395K(5)
|
Peer-Review Report-291K(30)
|
Answering Reviewers-97K(41)
|
Full Article (PDF)-967K(244)
|
Full Article (XML)-396K(43)
|
Times Cited (8)
|
Total Visits (4774)
|
Open
|
| 14 |
Elias Kouroumalis, Ioannis Tsomidis, Argyro Voumvouraki. Viral Liver Disease and Intestinal Gut–Liver Axis. Gastrointestinal Disorders 2024; 6(1): 64 doi: 10.3390/gidisord6010005
|
| 15 |
Tao Yang, Qijie Guan, Jin-Song Shi, Zheng-Hong Xu, Yan Geng. Metformin alleviates liver fibrosis in mice by enriching Lactobacillus sp. MF-1 in the gut microbiota. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2023; 1869(5): 166664 doi: 10.1016/j.bbadis.2023.166664
|